Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,411 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Occlusive Vascular Disease Clear all
Completed Phase 3 Interventional

Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions

NCT00371423
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté™-SR
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Little Rock, Arkansas • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 13, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 13, 2026, 8:59 AM EDT
Withdrawn Not applicable Interventional

Comparing Perclose to Statseal in Conjunction With Perclose in Femoral 6 French Arteriotomy Closure

NCT05468957
View directory record Official record
Conditions
Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma
Interventions
Perclose, Statseal
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

NCT00543400
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
M118, Unfractionated Heparin
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
19 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
37
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

NCT07023445
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37,688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational Results available

Study to Evaluate Cerebral AneurysmFlow Results in Occlusion

NCT03663257
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
AneurysmFlow
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 13, 2026, 8:59 AM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 13, 2026, 8:59 AM EDT
Terminated No phase listed Observational

Functional Assessment of Coronary Artery Disease by CTA Flow Encoding

NCT02286401
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Imaging of Plaque With Magnetic Resonance Imaging (MRI)

NCT00115856
View directory record Official record
Conditions
Arterial Occlusive Disease
Interventions
Intravascular MRI
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 80 Years
Enrollment
20 participants
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

NCT00616772
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Placebo, Atorvastatin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
45 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
124
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational

Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

NCT03886077
View directory record Official record
Conditions
Coronary Artery Disease, Morality
Interventions
glecaprevir/pibrentasivir
Drug
Lead sponsor
Sentara Norfolk General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging Correlates of Memory Decline Following Carotid Interventions

NCT02006095
View directory record Official record
Conditions
Carotid Artery Stenosis
Interventions
Magnetic resonance imaging, Neuropsychological testing
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 13, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional

MBA Early Feasibility Study

NCT07564375
View directory record Official record
Conditions
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
Interventions
GORE® Multibranch Arch Endoprosthesis, GORE® Ascending Stent Graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Los Angeles, California • Cleveland, Ohio • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)

NCT01628159
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Lutonix Drug Coated Balloon
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Los Angeles, California • Oceanside, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery

NCT00549796
View directory record Official record
Conditions
Coronary Arteriosclerosis, Angina Pectoris
Interventions
Percutaneous coronary intervention (PCI)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
60
States / cities
Huntsville, Alabama • Austell, Georgia • Brunswick, Georgia + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Multi-center, Single-arm Study of the Auryon Laser System for Treatment of Below-the-Knee (BTK) Arteries

NCT05284240
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Auryon Laser System
Device
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Miami Beach, Florida • Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 13, 2026, 8:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

NCT00326690
View directory record Official record
Conditions
Congestive Heart Failure, Ischemic Cardiomyopathy, Coronary Artery Disease, Myocardial Diseases
Interventions
Blue Egg Device
Device
Lead sponsor
BioVentrix
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • St. Petersburg, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 13, 2026, 8:59 AM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 8:59 AM EDT
Completed No phase listed Observational

Endothelial Function and Vein Graft Remodeling

NCT00831090
View directory record Official record
Conditions
Peripheral Arterial Disease, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 89 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity

NCT04717050
View directory record Official record
Conditions
Breast Cancer, Coronary Artery Disease, Stroke, Type2 Diabetes
Interventions
Progressive combine training (PCT), Attention Control (AC)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT06005597
View directory record Official record
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 13, 2026, 8:59 AM EDT